Dr. E.FRANS
ActiveSummary
Dr. E.FRANS has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €761,901 and a net result of €52,703. Equity has been growing by about 5% per year since 2018. Its solvency ranks better than 76% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 27-05-2008 Normal situation
- Activity
- Specialist medical practice NACE 86220and 1 other
- Establishment unit
- 2.186.470.763 3140 Keerbergen, since 27-05-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 23-12-2024
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts 2025
- Gross margin
- €105,128
- ▼ 17.9%
- Turnover
- ≈ €200,000
- estimated
- Profit
- €52,703
- ▼ 27.0%
- Equity
- €761,901
- ▲ 7.4%
- Total assets
- €899,633
- ▼ 14.1%
Filed on 29-06-2026, 32 days before the deadline
Score breakdownlowers riskSector: Human health activities (NACE 86)Size: total assets €899,633Figures for financial year 2025 (filed on 29-06-2026)Equity €761,901 (84.7% of total assets)Show the evidence
Checked score
Score 2025
93
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 45% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency
100+7
equity 84.7% of total assets
Liquidity
55-6
short-term debt 15.3% · cash 6.8%
Profitability
76+4
return on assets 5.9%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%● unchanged vs 07-2025lowest value
09-2025: < 0.1%● unchanged vs 08-2025lowest value
10-2025: < 0.1%● unchanged vs 09-2025lowest value
11-2025: < 0.1%● unchanged vs 10-2025lowest value
12-2025: < 0.1%● unchanged vs 11-2025lowest value
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €70,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 6.47 (3.04 in 2024), above the usual 1.5. Short-term debt is 15.3% and cash 6.8% of total assets. 15.3% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 31% on liquidity, 20% on profitability and 49% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
32 days early
2024
28 days early
2023
34 days early
2022
17 days early
2021
8 days late
2020
55 days late
2019
89 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 6 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 29-06-2026 at the NBB all 18 filings
Turnover
≈ €200,000
Estimated: probably between €170,000 and €260,000
Total assets
€899,633▼ 14.1%
2024 · €1.0m
Net result
€52,703▼ 27.0%
2024 · €72,239
Working capital
€752,785▲ 9.3%
2024 · €688,846
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result for 2025 is 19% lower than in 2024 and the lowest since 2021.
Operating result€0.09m
2025
Net result€0.05m
2025
Total assets€0.9m
2025
Equity€0.8m
2025
Debt€0.1m
2025
Working capital€0.8m
2025
Return on assets (ROA)5.9%
2025
Solvency84.7%
2025
Current ratio6.47
2025
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Human health activities (NACE 86). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.1m-€0.2m▲ 24.4%€0.2m▲ 5.7%€0.2m▲ 13.0%€0.3m▲ 45.9%€0.1m▼ 59.4%€0.1m▲ 0.3%€0.09m▼ 19.2%
Net result€0.09m-€0.1m▲ 21.2%€0.1mwithin the sector's middle half▲ 10.9%€0.1mabove the sector's middle half▲ 19.4%€0.2mabove the sector's middle half▲ 37.2%€0.08mwithin the sector's middle half▼ 59.6%€0.07mwithin the sector's middle half▼ 5.7%€0.05mwithin the sector's middle half▼ 27.0%
Equity€0.5m-€0.6m▲ 21.7%€0.7mwithin the sector's middle half▲ 19.8%€0.7mabove the sector's middle half▼ 6.0%€0.8mabove the sector's middle half▲ 21.4%€0.6mabove the sector's middle half▼ 20.5%€0.7mabove the sector's middle half▲ 11.3%€0.8mabove the sector's middle half▲ 7.4%
Total assets€0.6m-€0.8m▲ 20.4%€0.9mwithin the sector's middle half▲ 13.0%€1.0mabove the sector's middle half▲ 16.3%€1.0mabove the sector's middle half▲ 2.2%€1.0mabove the sector's middle half▼ 1.4%€1.0mabove the sector's middle half▲ 2.3%€0.9mabove the sector's middle half▼ 14.1%
Debt€0.2m-€0.2m▲ 16.7%€0.2m▼ 8.2%€0.4m▲ 108%€0.2m▼ 33.4%€0.4m▲ 63.3%€0.3m▼ 12.6%€0.1m▼ 59.3%
Working capital€0.5m-€0.6m▲ 24.3%€0.7mwithin the sector's middle half▲ 19.7%€0.6mabove the sector's middle half▼ 10.9%€0.8mabove the sector's middle half▲ 23.1%€0.6mabove the sector's middle half▼ 20.2%€0.7mabove the sector's middle half▲ 12.8%€0.8mabove the sector's middle half▲ 9.3%
Solvency75.1%-75.8%▲ 0.8pp80.4%within the sector's middle half▲ 4.5pp65.0%within the sector's middle half▼ 15.4pp77.2%within the sector's middle half▲ 12.2pp62.2%within the sector's middle half▼ 15.0pp67.7%within the sector's middle half▲ 5.5pp84.7%above the sector's middle half▲ 17.0pp
Current ratio3.93-4.12▲ 0.195.08within the sector's middle half▲ 0.962.75within the sector's middle half▼ 2.334.23within the sector's middle half▲ 1.482.58within the sector's middle half▼ 1.653.04within the sector's middle half▲ 0.466.47above the sector's middle half▲ 3.43
Return on assets (ROA)13.4%-13.5%▲ 0.1pp13.3%within the sector's middle half▼ 0.2pp13.6%within the sector's middle half▲ 0.4pp18.3%within the sector's middle half▲ 4.7pp7.5%below the sector's middle half▼ 10.8pp6.9%below the sector's middle half▼ 0.6pp5.9%below the sector's middle half▼ 1.0pp
above
within
below
The sector band is the middle half of the companies in Human health activities (NACE 86). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin are not published. The abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €899,633
Fixed assets
€9,116 ▼ 55.2%
Current assets
€890,517 ▼ 13.3%
Equity and liabilities €899,633
Equity
€761,901 ▲ 7.4%
Debt
€137,732 ▼ 59.3%
Debt's share of the balance-sheet total falls from 32.3% to 15.3%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€102,304▼
2024 · €123,469
Cash flow
€63,939▼
2024 · €82,947
Debt to equity
0.18▼
2024 · 0.48
ROE
6.9%▼
2024 · 10.2%
Interest coverage
9.67▲
2024 · 5.41
Debt ≤ 1 year
€137,732▼
2024 · €338,363
Income taxes
€33,165▲
2024 · €29,401
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €40,600 | €7,333 | - | €4,948 | - |
| Financial fixed assets | - | - | - | - | €0 |
| Depreciation and write-downs of the year | €6,307 | €9,164 | €9,927 | €10,708 | €11,236 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Comparable companies
These companies have the same main activity as Dr. E.FRANS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €771,000 and €849,000, founded between 2005 and 2009.
| Company | Founded | Total assets | Equity | Gross margin | Turnover | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|---|
| Dr. E.FRANS Keerbergen | 2008 | €899,633 | €761,901 | €105,128 | - | €52,703 | - | 2025 |
| Société chirurgicale Laurence Preud'Homme Esneux | 2009 | €849,444 | €385,693 | €96,852 | - | €59,501 | 0 | 2025 |
| DR. KRIS VAN HAVER Gavere | 2009 | €822,090 | €646,182 | €95,670 | - | €60,894 | - | 2025 |
| ALLERGOS Pecq | 2008 | €770,635 | €111,192 | €109,163 | - | €29,652 | - | 2025 |
| Dokter Joost De Ganck - Urologie Lochristi | 2009 | €799,535 | €545,334 | €112,810 | - | €81,546 | - | 2025 |
| Van Daele - Devroey Aalst | 2009 | €800,361 | €791,073 | €115,261 | - | €74,889 | - | 2025 |
| ENT Anderlecht | 2005 | €849,131 | €72,979 | €102,260 | €221,428 | -€29,999 | - | 2024 |
They were chosen from the 8,159 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 17,811 companies had the same profile as Dr. E.FRANS has now. Two years later, 0.3% had gone bankrupt and 96.5% were still going.
- Small
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.3%
went bankrupt
3.1%
stopped otherwise
96.5%
was still going
That fits the bankruptcy probability of Dr. E.FRANS itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for Dr. E.FRANS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €10,680 | €9,479 | €1,613 | €6,307 | €9,164 | €9,927 | €10,708 | €11,236 | ▲ 4.9% |
| Other operating charges640/8 | - | - | - | €2,542 | €4,751 | €3,630 | €4,649 | €2,824 | ▼ 39.3% |
| Gross operating margin9900 | €147,044 | €169,910 | €171,073 | €198,625 | €290,752 | €126,011 | €128,118 | €105,128 | ▼ 17.9% |
| Operating profit (loss)9901 | €127,718 | €158,871 | €167,940 | €189,776 | €276,838 | €112,455 | €112,761 | €91,068 | ▼ 19.2% |
| Financial income75/76B | - | - | - | €12,434 | €1,463 | €2,172 | €11,697 | €5,385 | ▼ 54.0% |
| Recurring financial income75 | €3,419 | €775 | €2,365 | €1,684 | €1,463 | €2,172 | €11,697 | €5,385 | ▼ 54.0% |
| Non-recurring financial income76B | - | - | - | €10,750 | - | - | - | - | - |
| Financial charges65/66B | - | - | - | €6,622 | €6,652 | €8,607 | €22,817 | €10,584 | ▼ 53.6% |
| Recurring financial charges65 | €7,856 | €7,450 | €6,748 | €6,622 | €6,652 | €8,607 | €22,817 | €10,584 | ▼ 53.6% |
| Profit (loss) for the period before taxes9903 | €123,282 | €152,195 | €163,556 | €195,588 | €271,650 | €106,021 | €101,641 | €85,869 | ▼ 15.5% |
| Income taxes67/77 | €37,189 | €47,871 | €47,832 | €57,366 | €81,978 | €29,405 | €29,401 | €33,165 | ▲ 12.8% |
| Profit (loss) for the period9904 | €86,093 | €104,325 | €115,724 | €138,223 | €189,671 | €76,616 | €72,239 | €52,703 | ▼ 27.0% |
| Profit (loss) for the period to be appropriated9905 | €86,093 | €104,325 | €115,724 | €138,223 | €189,671 | €76,616 | €72,239 | €52,703 | ▼ 27.0% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €0.6m | €0.8m | €0.9m | €1.0m | €1.0m | €1.0m | €1.0m | €0.9m | ▼ 14.1% |
| Fixed assets21/28 | €0.01m | €0.003m | €0.004m | €0.04m | €0.04m | €0.03m | €0.02m | €0.009m | ▼ 55.2% |
| Tangible fixed assets22/27 | €0.01m | €0.002m | €0.003m | €0.04m | €0.04m | €0.03m | €0.02m | €0.008m | ▼ 58.0% |
| Furniture and vehicles24 | - | - | - | €0.04m | €0.04m | €0.03m | €0.02m | €0.008m | ▼ 58.0% |
| Financial fixed assets28 | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | = |
| Current assets29/58 | €0.6m | €0.8m | €0.9m | €1.0m | €1.0m | €1.0m | €1.0m | €0.9m | ▼ 13.3% |
| Amounts receivable within one year40/41 | €0.001m | €0.001m | - | - | - | - | €0.001m | €0.006m | ▲ 868% |
| Trade receivables40 | - | - | - | - | - | - | €0.001m | €0.003m | ▲ 423% |
| Other amounts receivable41 | - | - | - | - | - | - | - | €0.003m | - |
| Current investments50/53 | €0.1m | €0.3m | €0.4m | €0.5m | €0.5m | €0.7m | €0.8m | €0.8m | ▲ 3.4% |
| Cash at bank and in hand54/58 | €0.5m | €0.4m | €0.4m | €0.5m | €0.5m | €0.3m | €0.2m | €0.06m | ▼ 70.3% |
| Deferred charges and accrued income490/1 | - | - | - | €0.03m | €0.03m | €0.03m | €0.03m | €0.002m | ▼ 92.6% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €0.6m | €0.8m | €0.9m | €1.0m | €1.0m | €1.0m | €1.0m | €0.9m | ▼ 14.1% |
| Equity10/15 | €0.5m | €0.6m | €0.7m | €0.7m | €0.8m | €0.6m | €0.7m | €0.8m | ▲ 7.4% |
| Contributions10/11 | €0.2m | €0.2m | - | €0.2m | €0.2m | €0.01m | €0.01m | €0.01m | = |
| Reserves13 | €0.3m | €0.4m | €0.5m | €0.5m | €0.6m | €0.6m | €0.7m | €0.7m | ▲ 7.6% |
| Non-distributable reserves130/1 | - | - | - | €0.02m | €0.02m | €0 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €0.02m | €0.02m | €0 | - | - | - |
| Distributable reserves133 | - | - | - | €0.5m | €0.6m | €0.6m | €0.7m | €0.7m | ▲ 7.6% |
| Profit (loss) carried forward14 | - | - | - | - | - | €0 | €0 | - | - |
| Amounts payable17/49 | €0.2m | €0.2m | €0.2m | €0.4m | €0.2m | €0.4m | €0.3m | €0.1m | ▼ 59.3% |
| Amounts payable within one year42/48 | €0.2m | €0.2m | €0.2m | €0.4m | €0.2m | €0.4m | €0.3m | €0.1m | ▼ 59.3% |
| Financial debts43 | - | - | - | €0.004m | €0.004m | €0.006m | €0.02m | €0.007m | ▼ 54.3% |
| Credit institutions430/8 | - | - | - | €0.004m | €0.004m | €0.006m | €0.02m | €0.007m | ▼ 54.3% |
| Trade debts44 | €0.001m | €0.001m | €0.001m | €0.001m | €388 | €433 | €447 | €31 | ▼ 93.1% |
| Suppliers440/4 | - | - | - | €0.001m | €388 | €433 | €447 | €31 | ▼ 93.1% |
| Taxes, remuneration and social security45 | - | - | - | €0.02m | €0.03m | €0.01m | €0.03m | €0.007m | ▼ 79.3% |
| Taxes450/3 | - | - | - | €0.02m | €0.03m | €0.01m | €0.03m | €0.007m | ▼ 79.3% |
| Other amounts payable47/48 | - | - | - | €0.3m | €0.2m | €0.4m | €0.3m | €0.1m | ▼ 57.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €86,093 | €104,325 | €115,724 | €138,223 | €189,671 | €76,616 | €72,239 | €52,703 | ▼ 27.0% |
| + Depreciation and write-downs630 | €10,680 | €9,479 | €1,613 | €6,307 | €9,164 | €9,927 | €10,708 | €11,236 | ▲ 4.9% |
| Operating cash flow (approximation) | €96,772 | €113,804 | €117,338 | €144,530 | €198,835 | €86,542 | €82,947 | €63,939 | ▼ 22.9% |
| Investment in fixed assets (approximation) | - | €0 | -€2,433 | -€40,600 | -€7,083 | €0 | -€4,948 | €0 | - |
| Change in cash | - | -€108,692 | €23,294 | €32,251 | €23,448 | -€214,732 | -€66,508 | -€144,450 | ▼ 117% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 18 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 29-06-2026 | 2026-00232488 | NBB |
| 31-12-2024 | micro format | 03-07-2025 | 2025-00248614 | |
| 31-12-2023 | micro format | 27-06-2024 | 2024-00176177 | |
| 31-12-2022 | micro format | 14-07-2023 | 2023-00244875 | |
| 31-12-2021 | micro format | 08-08-2022 | 2022-20275396 | |
| 31-12-2020 | abbreviated format | 24-09-2021 | 2021-68300366 | |
| 31-12-2019 | abbreviated format | 28-10-2020 | 2020-64100563 | |
| 31-12-2018 | micro format | 14-06-2019 | 2019-18500435 | |
| 31-12-2017 | micro format | 04-07-2018 | 2018-28300213 | |
| 31-12-2016 | micro format | 25-07-2017 | 2017-34600499 |
Board & ownership
Directors
Directors
1 director, last change in 2023
FRANS Eric
Current
Director · appointed in the act of 09-10-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 29-06-2026
Owners and capital
Capital transactions
Capital over time
- 09-10-2023 Converted to unavailable equity
Articles of association
Capital, shares and profit
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- “Op naam, register van aandelen op naam met WVV-vermeldingen”
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “10, rechten verbonden aan aandelen geschorst tot dag beslissing van een voormelde opties indien geen enkele erfgenaam en/of legataris…”
Audit, dissolution and liquidation
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Algemene vergadering mag één of meerdere vereffenaars aanduiden,bevoegdheden omlijnen en vergoeding bepalen, om welke reden en op welk…”
Articles of association, deed of 09-10-2023 (in Dutch)
Network & group
Dr. E.FRANS shares no director with another company.
Companies at the same address
2 other companiesConnections & network
1 current directorThe network starts from the directors of Dr. E.FRANS. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
29-06
micro format · 32 days before the deadline
2025
31-12
Financial
Weakest financial yearnet €52,703 ▼27%
The net result drops to €52,703, the lowest from 2018 to 2025.
31-12
Financial
Liquidity more than doubledcurrent ratio 6.47
The current ratio rises from 3.04 to 6.47. Short-term debt falls from €338,363 to €137,732.
03-07
micro format · 28 days before the deadline
2024
27-06
micro format · 34 days before the deadline
2023
09-10
Gazette deed
Appointment: FRANS Eric (director)Amendment of the articles · Capital conversion · Reserve release12 points ▸
Gazette deed
Appointment: FRANS Eric (director)
Amendment of the articles · Capital conversion · Reserve release12 points ▸
- General meeting, “buitengewone algemene vergadering van aandeelhouders, besloten vennootschap” (deed in Dutch)
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “opheffing statutair onbeschikbare eigen vermogensrekening, beschikbaar voor uitkering” (deed in Dutch)
- Declaration, “voorlezing en toelichting door notaris van WVV-uitkeringsregels, uitkeringsbesluit AV heeft pas uitwerking na vaststelling bestuursorgaan dat vennootschap na ui…” (deed in Dutch)
- Other provision, “invoering mogelijkheid schriftelijke algemene vergadering” (deed in Dutch)
- Capital
- Other provision, “coördinatie opmaken en ondertekenen overeenkomstig vorig besluit en neerlegging in vennootschapsdossier verzorgen, opdracht coördinatie statuten” (deed in Dutch)
- Power of attorney, Filip Huygens
- Other provision, “omzetting zaakvoerder naar bestuurder van rechtswege, bestuurder” (deed in Dutch)
- Director appointment, FRANS Eric (director)
- Registered office clause, “Keerbergen, Achiel Cleynhenslaan 39 bus A” (deed in Dutch)
14-07
micro format · 17 days before the deadline
2022
31-12
Financial
Highest result from 2018 to 2025net €189,671 ▲37.2%
The operating result of €276,838 and the net result of €189,671 are both a record.
08-08
micro format · 8 days late
2021
24-09
abbreviated format · 55 days late
2020
28-10
abbreviated format · 89 days late
2019
31-12
Financial
Equity above €500,000equity €585,849 ▲21.7%
With a profit in every financial year since 2018, equity grows to €585,849.
Show earlier events
14-06
micro format · 47 days before the deadline
2018
04-07
micro format · 27 days before the deadline
2017
25-07
micro format · 6 days before the deadline
2008
13-06
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
Dr. E.FRANS in Dutch
Enterprise number
0898.348.474
Legal form
Private limited company
Status
Active, normale toestand
Founded
27-05-2008
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 09-10-2023 (in Dutch)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest, bijlage tot het Belgisch Staatsblad”
deed of 09-10-2023 (in Dutch)Registered office and establishments
Registered office
Achiel Cleynhenslaan 39, 3140 Keerbergen, Belgium
Establishment unit
Achiel Cleynhenslaan 39A, 3140 Keerbergen since 27-05-2008 · unit number 2.186.470.763
Activities
NACEBEL 202586220
Specialist medical practice main activity
86995
Nutrition and dietetics services
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 09-10-2023 (in Dutch)
“Het ter beschikking stellen van alle nodige middelen aan geneesheren,die tot de vennootschap zijn toegetreden; Het inrichten van algemene…”
7 activities
- Het ter beschikking stellen van alle nodige middelen aan geneesheren,die tot de vennootschap zijn toegetreden.
- Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder,die nuttig of nodig zijn voor de uitoefening van voornoemde activiteiten.
- De aankoop,het huren van alle medische apparatuur en begeleidende accommodaties voor de eigen praktijk.
- Het aanleggen van reserves ten einde alle nodige apparatuur en gebouwen,die noodzakelijk zijn om de bovenvermelde medische disciplines uit te voeren,aan te schaffen.
- De mogelijkheden scheppen om de geneesheren-vennoten toe te laten zich verder te bekwamen ten einde in hun disciplines aan de spits van de evolutie te blijven.
- De vennootschap kan roerende en onroerende goederen en rechten verwerven en beheren en rechtshandelingen dienaangaande stellen voor zover dit ondergeschikt blijft aan het maatschappelijk doel en kadert in het beheer als een goede huisvader,voor zover het burgerlijk karakter van de vennootschap niet in het gedrang komt en zonder dat deze activiteit een regelmatig en commercieel karakter mag krijgen.
- De vennootschap mag deelnemen aan alle verenigingen en vennootschappen die een gelijkaardig doel nastreven of die bijdragen tot de algehele verwezenlijking van het doel van de vennootschap,doch overeenkomsten die geneesheren niet mogen afsluiten met andere geneesheren of derden,zullen ook door de vennootschap niet mogen afgesloten worden.
Invoicing and payment
VAT number
BE 0898.348.474
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Sites & property
Location
Buildings and parcels at the addresses
Ground area
6,708 m²
Building footprint
450 m²
Building volume
2,498 m³
Tallest building: 9.4 m.
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 24472G0091/00D000 | Flanders | 3,696 m² | 1 · 262 m² | 9.4 m · 2 |
| 24472G0089/00G000 | Flanders | 3,012 m² | 1 · 188 m² | 8.2 m · 2 |